$9.19m for FY2025, $2.73m for June Q, 35.8% YoY growth. CQGR of 9.5% over 3 years. Does not include US Remplir revenue
Healthy cash buffer for now. But execution risk is real — the US launch could turn cash hungry quickly.
Burn rate >$3.5m/qtr with uncertain near-term payoff.
First use in US complete.first use is not equal to commercial traction. Come on
No detail on sales growth in Striate+ from BioHorizons — only vague praise like “momentum building"
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.27 |
Change
-0.010(0.78%) |
Mkt cap ! $309.6M | |||
| Open | High | Low | Value | Volume |
| $1.28 | $1.28 | $1.25 | $228.1K | 180.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 42250 | $1.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.28 | 3113 | 1 |
View Market Depth
| Last trade - 16.10pm 01/08/2025 (20 minute delay) ? |
| OCC (ASX) Chart |